EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.
| Revenue (TTM) | $70.53M |
| Gross Profit (TTM) | $30.00M |
| EBITDA | $-21.29M |
| Operating Margin | -26.20% |
| Return on Equity | -94.50% |
| Return on Assets | -18.30% |
| Revenue/Share (TTM) | $1.88 |
| Book Value | $0.52 |
| Price-to-Book | 6.41 |
| Price-to-Sales (TTM) | 1.84 |
| EV/Revenue | 1.867 |
| EV/EBITDA | 1165.78 |
| Quarterly Earnings Growth (YoY) | -62.20% |
| Quarterly Revenue Growth (YoY) | -19.00% |
| Shares Outstanding | $37.48M |
| Float | $28.53M |
| % Insiders | 9.85% |
| % Institutions | 38.98% |
Volatility is currently contracting